# Benefit-Risk Action Document (BRAD) Template

**Version:** 1.0
**Date:** [Date]
**Product:** [Product Name]
**Document Status:** [Draft / Final]

---

## EDUCATIONAL USE ONLY

This template is provided for educational purposes as part of the NexVigilant Benefit-Risk Intelligence Toolkit. It should NOT be used for regulatory submissions without appropriate internal review and validation.

---

## Document Control

| Version | Date | Author | Changes |
|---------|------|--------|---------|
| 0.1 | [Date] | [Name] | Initial draft |
| | | | |

---

## Executive Summary

*[Provide a 2-3 paragraph summary of the key benefit-risk conclusions and recommendations. This section should enable a senior decision-maker to understand the core message without reading the full document.]*

---

## Section 1: Decision Context

### 1.1 Decision to be Made

| Element | Description |
|---------|-------------|
| **Decision Type** | [Initial approval / Line extension / Label update / Other] |
| **Regulatory Pathway** | [Standard / Accelerated / Breakthrough / Other] |
| **Decision Deadline** | [PDUFA date or timeline] |

### 1.2 Indication and Population

| Element | Description |
|---------|-------------|
| **Proposed Indication** | [Full indication statement] |
| **Target Population** | [Patient characteristics, age, disease stage] |
| **Population Size** | [Estimated patient population] |
| **Exclusions** | [Key contraindications or exclusions] |

### 1.3 Therapeutic Context

| Element | Description |
|---------|-------------|
| **Disease Background** | [Brief description of disease/condition] |
| **Unmet Medical Need** | [High / Moderate / Low - with justification] |
| **Current Standard of Care** | [Existing treatments and their limitations] |
| **Comparator(s)** | [Active comparator / Placebo / Historical control] |

### 1.4 Product Overview

| Element | Description |
|---------|-------------|
| **Product Name** | [Brand name / Generic name] |
| **Mechanism of Action** | [Brief MOA description] |
| **Dosage and Administration** | [Route, dose, frequency] |
| **Development Program** | [Overview of clinical program] |

---

## Section 2: Benefit Assessment

### 2.1 Clinical Evidence Summary

| Study | Design | Population | Primary Endpoint | Key Results |
|-------|--------|------------|------------------|-------------|
| [Study 1] | [RCT/OLE/etc.] | [N=, characteristics] | [Endpoint] | [Result with CI] |
| [Study 2] | | | | |
| [Study 3] | | | | |

### 2.2 Primary Efficacy Endpoints

| Endpoint | Treatment | Comparator | Difference | 95% CI | p-value | Clinical Significance |
|----------|-----------|------------|------------|--------|---------|----------------------|
| [Endpoint 1] | | | | | | [Assessment] |
| [Endpoint 2] | | | | | | |

### 2.3 Secondary/Supportive Efficacy Endpoints

| Endpoint | Treatment | Comparator | Difference | 95% CI | Clinical Relevance |
|----------|-----------|------------|------------|--------|-------------------|
| [Endpoint 1] | | | | | |
| [Endpoint 2] | | | | | |

### 2.4 Subgroup Analyses

| Subgroup | Effect Size | Consistency with Overall | Notes |
|----------|-------------|-------------------------|-------|
| [Age groups] | | [Consistent / Different] | |
| [Gender] | | | |
| [Disease severity] | | | |
| [Prior treatment] | | | |

### 2.5 Benefit Summary

**Key Benefits:**
1. [Primary benefit statement with quantification]
2. [Secondary benefit statement]
3. [Additional benefits]

**Benefit Uncertainties:**
- [Key uncertainty 1]
- [Key uncertainty 2]

**Benefit Conclusion:**
*[Overall benefit assessment with confidence level]*

---

## Section 3: Risk Assessment

### 3.1 Overview of Safety Database

| Parameter | Value |
|-----------|-------|
| **Total Exposure** | [Patient-years] |
| **Controlled Trials** | [N patients, duration] |
| **Long-term Exposure** | [N patients >6 mo, >12 mo] |
| **Special Populations** | [Elderly, renal/hepatic impairment, etc.] |

### 3.2 Identified Risks

| Risk | Treatment<br/>Incidence | Comparator<br/>Incidence | Relative Risk | Severity | Manageability | Mitigation |
|------|------------------------|-------------------------|---------------|----------|---------------|------------|
| [Risk 1] | | | | [Mild/Mod/Severe/Fatal] | [High/Mod/Low] | [RMM description] |
| [Risk 2] | | | | | | |
| [Risk 3] | | | | | | |

### 3.3 Potential Risks

| Risk | Evidence Source | Concern Level | Monitoring Plan |
|------|-----------------|---------------|-----------------|
| [Risk 1] | [Class effect / Mechanism / Signal] | [High / Moderate / Low] | [Description] |
| [Risk 2] | | | |

### 3.4 Missing Information

| Information Gap | Impact on B-R | Plan to Address |
|-----------------|---------------|-----------------|
| [Long-term safety] | [Assessment] | [Post-marketing commitment] |
| [Special population] | | |
| [Drug interactions] | | |

### 3.5 Risk Summary

**Key Risks:**
1. [Primary risk statement with quantification]
2. [Secondary risk statement]
3. [Additional risks]

**Risk Uncertainties:**
- [Key uncertainty 1]
- [Key uncertainty 2]

**Risk Conclusion:**
*[Overall risk assessment with characterization of risk profile]*

---

## Section 4: Benefit-Risk Integration

### 4.1 Effects Table

| Outcome | Importance | Treatment | Comparator | Difference | Uncertainty | Favors |
|---------|------------|-----------|------------|------------|-------------|--------|
| **BENEFITS** | | | | | | |
| [Primary efficacy] | Critical | | | | [95% CI] | |
| [Secondary efficacy] | Important | | | | | |
| [PRO/QoL] | Important | | | | | |
| **RISKS** | | | | | | |
| [Serious AE 1] | Critical | | | | | |
| [AE 2] | Important | | | | | |
| [AE 3] | Moderate | | | | | |

### 4.2 Value Tree

```
Product Benefit-Risk
├── BENEFITS
│   ├── Efficacy
│   │   ├── [Primary endpoint]
│   │   ├── [Secondary endpoint]
│   │   └── [Supportive endpoints]
│   ├── Patient-Relevant Outcomes
│   │   ├── [Symptom improvement]
│   │   └── [Quality of life]
│   └── Convenience/Adherence
│       └── [Dosing considerations]
│
└── RISKS
    ├── Identified Risks
    │   ├── [Serious risk 1]
    │   ├── [Serious risk 2]
    │   └── [Common risks]
    ├── Potential Risks
    │   └── [Based on class/mechanism]
    └── Missing Information
        └── [Key gaps]
```

### 4.3 Quantitative Analysis (if applicable)

| Method | Result | Interpretation |
|--------|--------|----------------|
| [NNT/NNH] | NNT=[X], NNH=[Y] | [Interpretation] |
| [DOOR Win Ratio] | [Value] | [Interpretation] |
| [MCDA Score] | [Treatment: X, Comparator: Y] | [Interpretation] |

### 4.4 Benefit-Risk Balance Assessment

#### For the Proposed Population:

| Factor | Assessment | Rationale |
|--------|------------|-----------|
| **Magnitude of Benefits** | [Large / Moderate / Small] | |
| **Magnitude of Risks** | [Large / Moderate / Small] | |
| **Certainty of Evidence** | [High / Moderate / Low] | |
| **Unmet Need** | [High / Moderate / Low] | |
| **Availability of Alternatives** | [Yes / Limited / No] | |
| **Overall B-R Balance** | [Positive / Uncertain / Negative] | |

### 4.5 Benefit-Risk Summary Statement

*[Craft a clear, defensible summary statement following this template:]*

> For [target population], [Product Name] provides [key benefits] that [outweigh / are balanced against / do not outweigh] [key risks], when used according to the proposed labeling which includes [key mitigation measures].

---

## Section 5: Risk Management

### 5.1 Proposed Risk Minimization Measures

| Risk | RMM Type | Description | Rationale |
|------|----------|-------------|-----------|
| [Risk 1] | [Routine/Additional] | [SmPC, PIL, Guide, Program] | [Why this measure] |
| [Risk 2] | | | |

### 5.2 Pharmacovigilance Plan

| Activity | Objective | Timeline |
|----------|-----------|----------|
| [Routine PV] | [Standard safety monitoring] | [Ongoing] |
| [PASS/PMC 1] | [Specific objective] | [Timeline] |
| [PASS/PMC 2] | | |

---

## Section 6: Conclusions and Recommendations

### 6.1 Overall Conclusion

*[State the overall benefit-risk conclusion clearly]*

### 6.2 Recommendations

| # | Recommendation | Rationale | Priority |
|---|----------------|-----------|----------|
| 1 | [Action] | [Why] | [High/Med/Low] |
| 2 | | | |
| 3 | | | |

### 6.3 Conditions/Commitments

| # | Condition/Commitment | Timeline | Responsible Party |
|---|---------------------|----------|-------------------|
| 1 | [Description] | [Date] | [Team/Individual] |
| 2 | | | |

---

## Appendices

### Appendix A: Detailed Study Results
*[Include detailed efficacy and safety tables]*

### Appendix B: Subgroup Analysis Details
*[Include forest plots and subgroup data]*

### Appendix C: Risk Minimization Materials
*[Draft RMM documents if applicable]*

### Appendix D: References
*[List key references and data sources]*

---

## Document Sign-Off

| Role | Name | Signature | Date |
|------|------|-----------|------|
| Medical Lead | | | |
| Regulatory Lead | | | |
| Safety Lead | | | |
| Commercial Lead | | | |
| Project Lead | | | |

---

**NexVigilant** | *Empowerment Through Vigilance*

This template is part of the [Benefit-Risk Intelligence Toolkit](https://github.com/nexvigilant/nv-BR-toolkit).
